focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,756.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GSK quarterly sales slip but confirms 2023 guidance

Wed, 26th Apr 2023 07:55

(Alliance News) - Stocks in London were set to open lower on Wednesday as worries about the US banking sector returned.

Concern around the banking sector came to the fore again on Tuesday as shares in First Republic Bank collapsed by 49% in New York after it revealed customers pulled out more than USD100 billion of deposits last month.

The California-based lender said withdrawals had stabilised this month, but added that deposits continued to fall slightly.

The news brought back nervousness about the sector, having calmed recently following the chaos caused by the collapse of Silicon Valley Bank.

Other major US banks such as JPMorgan and Wells Fargo closed lower in response.

In London, pharmaceutical firm GSK reported lower turnover in the first quarter, due to lower Covid-19 related sales. Mexican miner Fresnillo said it made a solid start to 2023 as silver and gold production increased.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 17.23 points, or 0.2%, at 7,873.90

----------

Hang Seng: up 0.9% at 19,791.52

Nikkei 225: closed down 0.7% at 28,416.47

S&P/ASX 200: closed down 0.1% at 7,316.30

----------

DJIA: closed down 344.57 points, 1.0%, at 33,530.83

S&P 500: closed down 1.6% at 4,071.63

Nasdaq Composite: closed down 2.0% at 11,799.16

----------

EUR: higher at USD1.0995 (USD1.0983)

GBP: higher at USD1.2428 (USD1.2404)

USD: lower at JPY133.74 (JPY133.98)

Gold: higher at USD1,997.77 per ounce (USD1,987.63)

(Brent): higher at USD81.20 a barrel (USD80.52)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

11:00 BST UK CBI distributive trades survey

----------

German consumer morale rose sharply heading into May, a key survey showed, as concerns eased about the impact of high inflation on Europe's top economy. Pollster GfK said its forward-looking survey of around 2,000 people climbed 3.6 points to reach minus 25.7 points, the seventh consecutive monthly increase. Improving sentiment was driven by lower energy prices, government relief measures aimed at tackling high costs, and recent wage deals struck between various industries and workers, GfK said. "More and more households are assuming that feared losses in purchasing power due to inflation will turn out to be much milder," the pollster said.

----------

BROKER RATING CHANGES

----------

JPMorgan raises Associated British Foods price target to 1,850 (1,760) pence - 'neutral'

----------

Bernstein raises Whitbread price target to 3,150 (2,985) pence - 'market-perform'

----------

JPMorgan raises Travis Perkins price target to 850 (820) pence - 'underweight'

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm GSK said its sales performance in the first quarter of 2023 reflected lower Covid-19 solution sales compared to the previous year. When excluding this Covid-related business, sales grew 10% at constant exchange rates. In the quarter, turnover totalled GBP6.95 billion, down from GBP7.19 billion the previous year. Pretax profit was GBP1.91 billion, down from GBP2.29 billion the year prior. Adjusted operating profit rose by 8% on a year before to GBP2.09 billion, and adjusted operating profit margin was 30.1%, up 3.1 percentage points. Despite, the fall in turnover and pretax profit, GSK affirmed its full-year guidance, expecting turnover growth of between 6% and 8%. It declared a quarterly dividend of 14 pence per share. It said it expects to payout 56.5p per share in dividends in 2023.

----------

Fresnillo reported a "solid" start to 2023, noting silver and gold production were both up on the previous quarter thanks to an increasing contribution from its new Juanicipio mine. Quarterly attributable silver production totalled 13.1 million ounces, up 5.1% against the previous quarter but down 0.9% against the previous year as a result of lower ore grade and decreased volume of ore processed at San Julian. Quarterly attributable gold production totalled 173,000 ounces, up 3.0% against the previous quarter and up 16% against the previous year due to the higher volume of ore processed. Looking forward, the miner kept its full-year guidance unchanged. It sees attributable silver production in the range of 57.0 million to 64.0 million ounces and attributable gold production in the range of 590,000 to 640,000 ounces.

----------

COMPANIES - FTSE 250

----------

Drax said it delivered a "strong" system support and generation performance in the first three months of 2023, as it announced a GBP150 million share buyback programme. The renewable energy company said it expects 2023 adjusted earnings before interest, tax, depreciation and amortisation to be in-line with analyst consensus estimates, which it placed at GBP1.16 billion in a range of GBP1.1 billion to GBP1.2 billion. Drax noted that at the end of March it formally closed its two remaining coal units at the Drax Power Station.

----------

Harbour Energy announced that the Kan-1 exploration well has made an oil discovery in Block 30, offshore Mexico. The oil company holds a 30% interest in the block. The Block 30 partners will now evaluate the well data collected and put together a proposed plan to appraise the discovery, Harbour said.

----------

Specialty chemicals company Elementis said overall trading in the first quarter of 2023 has been "resilient" against subdued market demand conditions. It reported that revenue was flat on an underlying basis in the quarter as benefits from prior year pricing actions and improved mix broadly offset weaker volumes. In its Performance Specialties division, Elementis said its underlying performance was below the prior year period due to continued challenging demand conditions across coatings markets. In its Personal Care division, its underlying performance improved on the prior year as volumes were broadly stable due to new product launches and new business success, which helped to offset market weakness in Asia. Chief Executive Paul Waterman said: "We have made a solid start to the year and will continue to maintain our focus on self-help actions and effectively managing the challenging demand environment. We remain on-track to deliver over USD50 million of new business opportunities, 15 new products and progress towards USD10 million of additional efficiency savings by year end."

----------

OTHER COMPANIES

----------

Unikmind Holdings said it bought 12.0 million more shares in Kape Technologies, representing a further 2.8% of its shares. The acquisition means that Unikmind now holds or has acceptances for its takeover offer totalling 79% of Kape shares. Unikmind's offer is USD3.60 per Kape share.

----------

Breedon said that trading during the first quarter of 2023 has been "positive", with "encouraging" levels of enquiries. Revenue in the quarter is expected to be 10% ahead of the same period last year, or 7% ahead on a like-for-like basis. As a result, the construction materials firm said it is trading in-line with expectations, which it did not specify. Chief Executive Rob Wood said: "Our teams have stayed close to their customers and we continue to manage our cost base prudently, enabling us to grow revenue while fully recovering input cost increases. Longer term, our end-market exposure remains underpinned by structural growth dynamics."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
9 Apr 2024 11:45

Pfizer RSV shot meets goals in trial of high-risk adults under age 60

April 9 (Reuters) - Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60 similar to that in older adults, for whom the shot is already approved.

Read more
8 Apr 2024 09:13

LONDON BROKER RATINGS: Wizz Air raised; HSBC cuts Rentokil to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
4 Apr 2024 13:08

UK dividends calendar - next 7 days

Friday 5 April 
BBGI Global Infrastructure SAdividend payment date
Molten Ventures PLCdividend payment date
Pennon Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
Regional REIT Ltddividend payment date
Rights & Issues Investment Trust PLCdividend payment date
Sylvania Platinum Ltddividend payment date
Titon Holdings PLCdividend payment date
Triple Point Energy Transition PLCdividend payment date
Monday 8 April 
Alumasc Group PLCdividend payment date
LondonMetric Property PLCdividend payment date
Redrow PLCdividend payment date
Tuesday 9 April 
CT Global Managed Portfolio Trust PLCdividend payment date
Downing Strategic Micro-Cap Investment Trust PLCdividend payment date
Dunelm Group PLCspecial dividend payment date
Hays PLCdividend payment date
Renishaw PLCdividend payment date
Safestore Holdings PLCdividend payment date
Wednesday 10 April 
Assura PLCdividend payment date
Primorus Investments PLCspecial dividend payment date
Wilmington PLCdividend payment date
Thursday 11 April 
Amedeo Air Four Plus Ltdex-dividend payment date
Athelney Trust PLCdividend payment date
Aviva PLCex-dividend payment date
Balanced Commercial Property Trust Ltdex-dividend payment date
Barratt Developments PLCex-dividend payment date
Begbies Traynor Group PLCex-dividend payment date
Bioventix PLCex-dividend payment date
Blackfinch Spring VCT PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
Caledonia Mining Corpex-dividend payment date
Capital & Regional PLCex-dividend payment date
Chesnara PLCex-dividend payment date
Colefax Group PLCdividend payment date
CT Private Equity Trust PLCex-dividend payment date
Downing Strategic Micro-Cap Investements Trust PLCex-dividend payment date
Driver Group PLCdividend payment date
F&C Investment Trust PLCex-dividend payment date
Foxtons Group PLCex-dividend payment date
Grafton Group PLCex-dividend payment date
GSK PLCdividend payment date
Harbour Energy PLCex-dividend payment date
Hargreaves Services PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
Hunting PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
International Personal Finance PLCex-dividend payment date
International Public Partnerships Ltdex-dividend payment date
ITV PLCex-dividend payment date
Johnson Service Group PLCex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Just Group PLCex-dividend payment date
Kenmare Resources PLCex-dividend payment date
Kerry Group PLCex-dividend payment date
Kings Arms Yard VCT PLCex-dividend payment date
Law Debenture Corp PLCdividend payment date
Lloyds Banking Group PLCex-dividend payment date
Lowland Investment Cos PLCex-dividend payment date
Luceco PLCex-dividend payment date
Man Group PLCex-dividend payment date
Manchester & London Investement Trust PLCex-dividend payment date
Marble Point Loan Financing Ltdex-dividend payment date
Mercantile Investment Trust PLCex-dividend payment date
Mobius Investment Trust PLCex-dividend payment date
MTI Wireless Edge Ltddividend payment date
North American Income Trust PLCex-dividend payment date
Northamber PLCex-dividend payment date
Octopus Apollo VCT PLCex-dividend payment date
Phoenix Group Holdings PLCex-dividend payment date
Reckitt Benckiser Group PLCex-dividend payment date
Ricardo PLCdividend payment date
Savills PLCex-dividend payment date
Schroder Asian Total Return Investment Cos PLCex-dividend payment date
Schroder European Real Estate Investment Trust PLCex-dividend payment date
Scottish American Investment Cos PLCdividend payment date
Smurfit Kappa Group PLCex-dividend payment date
Softcat PLCex-dividend payment date
Somero Enterprises Incex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Synectics PLCex-dividend payment date
TP ICAP Group PLCex-dividend payment date
Trifast PLCdividend payment date
TT Electronics PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.